Tag: Daniel Greenleaf

DENVER - Company officials at BioScrip blamed a second straight quarter of net revenue declines on several “disrupters,” both expected and unexpected.The declines primarily stem fromBioScrip's exit from a UnitedHealthcare contract and the double whammy of Hurricanes Harvey and Irma, said CEO Daniel Greenleaf, CEO, during a Nov. 2 earnings call.“Disruption from the hurricanes and the UnitedHealthcare contract transition decreased revenue by an estimated $10 million during the quarter,”...

DENVER - BioScrip has announced a plan to increase its liquidity.The home infusion and home care provider has proposed an amendment to its original credit agreement that would restructure an existing revolving credit facility, providing immediate access to $15 million.BioScrip has suffered losses in recent quarters. Net revenues for the third quarter of 2016 were $224.5 million, a decrease of 9.2% from a year ago. Net losses from continuing operations were $11.1 million vs. $24.5 million.The company...

Daniel Greenleaf is in a familiar position. The new president and CEO of BioScrip is tasked with turning around an underperforming home infusion company, which he did with both Coram and, more recently, with Home Solutions.“Under my leadership, my team and I developed and led transformational change resulting in Home Solutions becoming one of the top performing infusion services providers n the country,” said Greenleaf during a recent earnings call. “I see many similarities between...

DENVER - With revenues at BioScrip sliding again in the third quarter, new President and CEO Daniel Greenleaf didn't mince words on a recent earnings call.“Clearly, the organization took its eye off the ball in the third,” he said. “The people that were involved are no longer part of the organization in any way, shape or form.”Greenleaf took the reins in September when BioScrip completed its acquisition of HS Holdings, where he had served as CEO since 2014. Prior to that,...

WASHINGTON - As this year's congressional session winds down, HME stakeholders are eyeing the “doc-fix” bill as the best vehicle for H.R. 1717. The Senate Finance and House Ways and Means committees are expected to mark up the doc fix bill on Thursday, according to Cara Bachenheimer, senior vice president of government relations for Invacare. If a finalized fix to physician reimbursement is delayed, it would give the industry more time to push H.R. 1717, which has 160 co-sponsors, said...

DENVER - Daniel Greenleaf is now president and CEO of specialty-infusion company Home Solutions, the Denver Post reports. “His strong executive skills and commercial and operations background bring crucial elements to achieve significant growth, operational efficiencies and continued success for Home Solutions,” said Steve Neumann, managing partner of KRG Capital Partners. Greenleaf joined Apria as president of Coram Specialty Infusion in 2008, which CVS Caremark purchased last week...